Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China

Neoplasma

Volumn 59, Issue 1, 2012, Pages 100-104

  Lu, H Y ^a   Sun, W Y ^a   Chen, B ^a   Zhang, Y P ^a   Cai, J F ^a   Su, D ^a   Wang, Z ^a   Zheng, Y Q ^b   Ma, S L ^c  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b Guangzhou Technology Innovation Base   (China)

^c HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

EGFR; Gene mutation; SCLC; XTAG technology

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA POLYMERASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; IRINOTECAN; RECOMBINANT ENDOSTATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; ENDOSTAR PROTEIN; ENDOSTATIN; TAXOID;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRAIN RADIATION; CHINA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLUORESCENCE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; CASE REPORT; EXON; GENETICS; INCIDENTAL FINDING; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TUMOR; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; MUTATION; PROTO ONCOGENE; SKULL IRRADIATION; SMALL CELL CARCINOMA; SMOKING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CHINA; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; ENDOSTATINS; EXONS; FEMALE; GENES, ERBB-1; HUMANS; INCIDENTAL FINDINGS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; PNEUMONECTOMY; SMOKING; TAXOIDS; YOUNG ADULT;

EID: 84859447774     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_013     Document Type: Article

References (12)

1. OKAMOTO I, ARAKI J, SUTO R et al. EGFR mutation in gefitinib responsive small-cell lung cancer. Annals of Oncology,2006, 17: 1028-1029. http://dx.doi.org/10.1093/annonc/mdj114
2. ZAKOWSKI MF, LADANYI M, KRIS MG et al. EGFR Mutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked. N Engl J Med, 2006, 355: 213-215. http://dx.doi.org/10.1056/NEJMc053610
3. QIAN JUN, QIN SHU-KUI, TANG QING-QING et al. Gefitinib in patients with advanced refractory small cell lung cancer contemporaneous with superior venacava syndrome. Chinese Clinical Oncology, 2005, 10: 243-244.
4. SHIAO TH, CHANG YL, YU CJ et al. Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. J Thorac Oncol, 2011, 5: 195-198. http://dx.doi.org/10.1097/JTO.0b013e3181f94abb
5. AKIKO TATEMATSU, JUNICHI SHIMIZU, YOSHIKO MURAKAMI et al. Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer. Clin Cancer Res, 2008, 14: 6093-6096. http://dx.doi.org/10.1158/1078-0432.CCR-08-0332
6. SHIGEMATSU H, LIN L, TAKAHASHI T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005, 97: 339-346. http://dx.doi.org/10.1093/jnci/dji055
7. WU YL, ZHONG WZ, LI LY et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol, 2007, 2: 430-439. http://dx.doi.org/10.1097/01.JTO.0000268677.87496.4c
8. NICHOLSON SA, BEASLEY MB, BRAMBILLA E et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol, 2002, 26: 1184-1197. http://dx.doi.org/10.1097/00000478-200209000-00009
9. GUOQIANG LI, XIAODI LUO, JIAYING HE et al. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med, 2011, 49: 191-195. http://dx.doi.org/10.1515/CCLM.2011.040
10. PAO W, LADANYI M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res, 2007, 13: 4954-4955. http://dx.doi. org/10.1158/1078-0432.CCR-07-1387
11. DAHABREH IJ, LINARDOU H, SIANNIS F et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res, 2010, 16: 291-303. http://dx.doi. org/10.1158/1078-0432.CCR-09-1660
12. ZHU JQ, ZHONG WZ, ZHANG GC et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett, 2008, 265: 307-317. http://dx.doi.org/10.1016/j.canlet.2008.02.064